JP2019506363A - Ａｐｒｉｌに対する抗体分子およびその使用 - Google Patents

Ａｐｒｉｌに対する抗体分子およびその使用 Download PDF

Info

Publication number
JP2019506363A
JP2019506363A JP2018526763A JP2018526763A JP2019506363A JP 2019506363 A JP2019506363 A JP 2019506363A JP 2018526763 A JP2018526763 A JP 2018526763A JP 2018526763 A JP2018526763 A JP 2018526763A JP 2019506363 A JP2019506363 A JP 2019506363A
Authority
JP
Japan
Prior art keywords
amino acid
less
acid sequence
seq
antibody molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018526763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506363A5 (https=
Inventor
ジェイムズ アール． マイエット，
ジェイムズ アール． マイエット，
ザッカリー ホームズ シュリバー，
ザッカリー ホームズ シュリバー，
カルシク ビスワナサン，
カルシク ビスワナサン，
アンドリュー エム． ウーラコット，
アンドリュー エム． ウーラコット，
ヘディ アダリ−ホール，
ヘディ アダリ−ホール，
ブーパシー ラマクリシュナン，
ブーパシー ラマクリシュナン，
グレゴリー バブコック，
グレゴリー バブコック，
Original Assignee
ビステラ， インコーポレイテッド
ビステラ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビステラ， インコーポレイテッド, ビステラ， インコーポレイテッド filed Critical ビステラ， インコーポレイテッド
Publication of JP2019506363A publication Critical patent/JP2019506363A/ja
Publication of JP2019506363A5 publication Critical patent/JP2019506363A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2018526763A 2015-11-25 2016-11-23 Ａｐｒｉｌに対する抗体分子およびその使用 Ceased JP2019506363A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562259897P 2015-11-25 2015-11-25
US62/259,897 2015-11-25
US201662313684P 2016-03-25 2016-03-25
US62/313,684 2016-03-25
US201662399087P 2016-09-23 2016-09-23
US62/399,087 2016-09-23
US201662422848P 2016-11-16 2016-11-16
US62/422,848 2016-11-16
PCT/US2016/063518 WO2017091683A1 (en) 2015-11-25 2016-11-23 Antibody molecules to april and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021132222A Division JP7029018B2 (ja) 2015-11-25 2021-08-16 Ａｐｒｉｌに対する抗体分子およびその使用

Publications (2)

Publication Number Publication Date
JP2019506363A true JP2019506363A (ja) 2019-03-07
JP2019506363A5 JP2019506363A5 (https=) 2020-01-09

Family

ID=57543212

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018526763A Ceased JP2019506363A (ja) 2015-11-25 2016-11-23 Ａｐｒｉｌに対する抗体分子およびその使用
JP2021132222A Active JP7029018B2 (ja) 2015-11-25 2021-08-16 Ａｐｒｉｌに対する抗体分子およびその使用
JP2022022801A Withdrawn JP2022068288A (ja) 2015-11-25 2022-02-17 Ａｐｒｉｌに対する抗体分子およびその使用
JP2024043460A Pending JP2024073611A (ja) 2015-11-25 2024-03-19 Ａｐｒｉｌに対する抗体分子およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021132222A Active JP7029018B2 (ja) 2015-11-25 2021-08-16 Ａｐｒｉｌに対する抗体分子およびその使用
JP2022022801A Withdrawn JP2022068288A (ja) 2015-11-25 2022-02-17 Ａｐｒｉｌに対する抗体分子およびその使用
JP2024043460A Pending JP2024073611A (ja) 2015-11-25 2024-03-19 Ａｐｒｉｌに対する抗体分子およびその使用

Country Status (27)

Country Link
US (9) US20170145086A1 (https=)
EP (2) EP4285923A3 (https=)
JP (4) JP2019506363A (https=)
KR (2) KR102747820B1 (https=)
CN (3) CN109089419B (https=)
AU (2) AU2016361488B2 (https=)
CA (1) CA3006058A1 (https=)
CL (2) CL2018001372A1 (https=)
CO (1) CO2018006461A2 (https=)
DK (1) DK3380522T5 (https=)
ES (1) ES2970864T3 (https=)
FI (1) FI3380522T3 (https=)
HK (1) HK1254337A1 (https=)
HR (1) HRP20231578T1 (https=)
HU (1) HUE064791T2 (https=)
IL (2) IL259585B2 (https=)
LT (1) LT3380522T (https=)
MA (1) MA43308A (https=)
MX (2) MX2018006385A (https=)
MY (1) MY197345A (https=)
PL (1) PL3380522T3 (https=)
PT (1) PT3380522T (https=)
SA (1) SA518391659B1 (https=)
SG (1) SG11201804309PA (https=)
SI (1) SI3380522T1 (https=)
WO (1) WO2017091683A1 (https=)
ZA (1) ZA201803366B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021184740A (ja) * 2015-11-25 2021-12-09 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用
JP2023508173A (ja) * 2019-12-24 2023-03-01 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
JP2023531722A (ja) * 2020-06-24 2023-07-25 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210340266A1 (en) * 2008-10-09 2021-11-04 Visterra, Inc. Antibody molecules to april and uses thereof
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
WO2020139834A1 (en) * 2018-12-24 2020-07-02 Visterra, Inc. Methods for identifying epitopes and paratopes
AU2020225631A1 (en) 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
CN110522902B (zh) * 2019-09-25 2022-10-11 南京农业大学 一种用于建立慢性肾病模型的组合物及其应用
IL296358A (en) * 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
AR123935A1 (es) 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒
US20240228626A1 (en) * 2021-05-04 2024-07-11 Immunorizon Ltd. Anti-nkg2d antibodies and uses thereof
KR20240019124A (ko) 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
KR20240021179A (ko) * 2021-05-14 2024-02-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 폴리펩티드 및 사용 방법
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
US20240092921A1 (en) * 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
CN119930816A (zh) * 2023-11-02 2025-05-06 广东菲鹏制药股份有限公司 抗cd39人源化抗体或其抗原结合片段及其应用
WO2026067804A1 (zh) * 2024-09-30 2026-04-02 信立泰(成都)生物技术有限公司 一种抗april抗体或其抗原结合片段及用途

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537290A (ja) * 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
JP2011500073A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
JP2011501945A (ja) * 2007-10-17 2011-01-20 ヤンセン アルツハイマー イミュノセラピー ＡｐｏＥ状態に依存する免疫療法レジメ
JP2011502126A (ja) * 2007-10-31 2011-01-20 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体
JP2011523037A (ja) * 2008-05-01 2011-08-04 ザイモジェネティクス， インコーポレイテッド 血清中のＢＬｙＳ／ＡＰＲＩＬヘテロ三量体レベルおよび診断方法における使用
US20120201823A1 (en) * 2009-10-14 2012-08-09 Schering Corporation April antagonists and methods of use
JP2012519198A (ja) * 2009-03-02 2012-08-23 スティヒティング・トップ・インスティテュート・ファルマ 増殖誘導リガンド（ａｐｒｉｌ）に対する抗体
JP2013512258A (ja) * 2009-11-30 2013-04-11 ヤンセン バイオテツク，インコーポレーテツド 除去されたエフェクター機能を伴う抗体Ｆｃ突然変異
JP2013541522A (ja) * 2010-09-16 2013-11-14 バリオファルム・アクチェンゲゼルシャフト 抗ｈｕＴＮＦＲ１抗体
JP2014523408A (ja) * 2011-06-06 2014-09-11 ノヴォ ノルディスク アー／エス 治療抗体
WO2014151680A1 (en) * 2013-03-15 2014-09-25 Biogen Idec Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2015069865A1 (en) * 2013-11-06 2015-05-14 Janssen Biotech, Inc. Anti-ccl17 antibodies

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
SK3542000A3 (en) 1997-09-12 2000-08-14 Apotech R & D Sa Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2396793A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
CA2554526A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
ATE500275T1 (de) * 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
JP5426531B2 (ja) 2007-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド 自己免疫疾患の治療のためのＢＬｙＳ阻害および／またはＡＰＲＩＬ阻害ならびに免疫抑制剤の組み合わせ
US20210340266A1 (en) 2008-10-09 2021-11-04 Visterra, Inc. Antibody molecules to april and uses thereof
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
CA2833820C (en) * 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3245230B1 (en) 2015-01-15 2020-12-16 Université Grenoble Alpes Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
CN105390742A (zh) * 2015-12-31 2016-03-09 石家庄圣泰化工有限公司 高电压锂离子电池电解液及其制备方法及应用
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
TW202216195A (zh) 2020-06-24 2022-05-01 美商威特拉公司 April抗體分子及其用途
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537290A (ja) * 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
JP2011501945A (ja) * 2007-10-17 2011-01-20 ヤンセン アルツハイマー イミュノセラピー ＡｐｏＥ状態に依存する免疫療法レジメ
JP2011500073A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
JP2011502126A (ja) * 2007-10-31 2011-01-20 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体
JP2011523037A (ja) * 2008-05-01 2011-08-04 ザイモジェネティクス， インコーポレイテッド 血清中のＢＬｙＳ／ＡＰＲＩＬヘテロ三量体レベルおよび診断方法における使用
JP2012519198A (ja) * 2009-03-02 2012-08-23 スティヒティング・トップ・インスティテュート・ファルマ 増殖誘導リガンド（ａｐｒｉｌ）に対する抗体
US20120201823A1 (en) * 2009-10-14 2012-08-09 Schering Corporation April antagonists and methods of use
JP2013512258A (ja) * 2009-11-30 2013-04-11 ヤンセン バイオテツク，インコーポレーテツド 除去されたエフェクター機能を伴う抗体Ｆｃ突然変異
JP2013541522A (ja) * 2010-09-16 2013-11-14 バリオファルム・アクチェンゲゼルシャフト 抗ｈｕＴＮＦＲ１抗体
JP2014523408A (ja) * 2011-06-06 2014-09-11 ノヴォ ノルディスク アー／エス 治療抗体
WO2014151680A1 (en) * 2013-03-15 2014-09-25 Biogen Idec Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2015069865A1 (en) * 2013-11-06 2015-05-14 Janssen Biotech, Inc. Anti-ccl17 antibodies

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021184740A (ja) * 2015-11-25 2021-12-09 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用
JP7029018B2 (ja) 2015-11-25 2022-03-02 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用
JP2023508173A (ja) * 2019-12-24 2023-03-01 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
JP7686000B2 (ja) 2019-12-24 2025-05-30 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
JP2023531722A (ja) * 2020-06-24 2023-07-25 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用

Also Published As

Publication number Publication date
KR102747820B1 (ko) 2024-12-27
ZA201803366B (en) 2025-09-25
SA518391659B1 (ar) 2022-12-13
JP7029018B2 (ja) 2022-03-02
EP3380522A1 (en) 2018-10-03
MX2018006385A (es) 2019-09-11
JP2024073611A (ja) 2024-05-29
US20190092851A1 (en) 2019-03-28
CN109089419B (zh) 2024-03-01
CL2018001372A1 (es) 2018-11-23
EP4285923A3 (en) 2024-03-06
KR20180091849A (ko) 2018-08-16
DK3380522T5 (da) 2024-09-30
JP2022068288A (ja) 2022-05-09
US20200331995A1 (en) 2020-10-22
US10385123B2 (en) 2019-08-20
US10968270B2 (en) 2021-04-06
CN109089419A (zh) 2018-12-25
CN118420760A (zh) 2024-08-02
CA3006058A1 (en) 2017-06-01
IL259585B2 (en) 2024-11-01
US20200317770A1 (en) 2020-10-08
NZ782617A (en) 2025-06-27
MA43308A (fr) 2018-10-03
PT3380522T (pt) 2024-02-14
AU2023201698A1 (en) 2023-04-20
IL259585A (en) 2018-07-31
AU2016361488B2 (en) 2022-12-22
ES2970864T3 (es) 2024-05-31
EP4285923A2 (en) 2023-12-06
US20210032324A1 (en) 2021-02-04
DK3380522T3 (da) 2024-01-22
IL313508A (en) 2024-08-01
AU2016361488A1 (en) 2018-06-14
MX2024010175A (es) 2024-08-27
SI3380522T1 (sl) 2024-02-29
WO2017091683A1 (en) 2017-06-01
KR20250008787A (ko) 2025-01-15
LT3380522T (lt) 2024-02-26
NZ742879A (en) 2025-06-27
US20170145086A1 (en) 2017-05-25
JP2021184740A (ja) 2021-12-09
CN118027201A (zh) 2024-05-14
WO2017091683A8 (en) 2022-12-15
IL259585B1 (en) 2024-07-01
MY197345A (en) 2023-06-14
US10954296B2 (en) 2021-03-23
HUE064791T2 (hu) 2024-04-28
HK1254337A1 (zh) 2019-07-19
PL3380522T3 (pl) 2024-03-25
CL2024000276A1 (es) 2024-08-30
FI3380522T3 (fi) 2024-01-16
US20200299376A1 (en) 2020-09-24
US20190330326A1 (en) 2019-10-31
CO2018006461A2 (es) 2018-08-31
HRP20231578T1 (hr) 2024-03-15
EP3380522B1 (en) 2023-11-08
US20220235124A1 (en) 2022-07-28
BR112018010673A2 (pt) 2018-11-13
RU2018122452A3 (https=) 2020-05-13
NZ782606A (en) 2025-06-27
US10981982B2 (en) 2021-04-20
RU2018122452A (ru) 2019-12-25
US20250066464A1 (en) 2025-02-27
US12091451B2 (en) 2024-09-17
SG11201804309PA (en) 2018-06-28
US11136385B2 (en) 2021-10-05
BR112018010673A8 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
JP7029018B2 (ja) Ａｐｒｉｌに対する抗体分子およびその使用
US20210340266A1 (en) Antibody molecules to april and uses thereof
JP2023531722A (ja) Ａｐｒｉｌに対する抗体分子およびその使用
HK40103484A (en) Antibody molecules to april and uses thereof
RU2793755C2 (ru) Молекулы антител против april и их применения
US20260116988A1 (en) Antibody molecules to april and uses thereof
HK40110880A (zh) April的抗体分子及其应用
HK40114871A (zh) April的抗体分子及其应用
BR112018010673B1 (pt) Moléculas de anticorpo para april, composição, uso das mesmas, molécula de ácido nucléico, vetor, kit e método de detecção de uma molécula de april

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210714

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20211022